Back to Stocks

ALGS

Aligos Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Aligos Therapeutics is successfully transitioning from a speculative research entity to a clinical-stage biotech with a clear path toward monetization.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of clinical progress, Aligos remains in a precarious financial position. The company's balance sheet reveals a steady erosion of liquidity, with cash and short-term investments falling to $54.9 million as of March 31, 2026.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ALGS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a stark dichotomy between clinical promise and financial instability. On the scientific front, Aligos is hitting key markers with pevifoscorvir sodium, moving into a pivotal Phase 2 study that could fundamentally re-rate the company's value. The Amoytop deal serves as a vital bridge, providing both cash and a professional endorsement of the company's capsid assembly modulator platform. However, the financial reality is a race against time. The 'going concern' warning is the dominant signal for investors, suggesting that the clinical success of the B-SUPREME trial must arrive before the cash reserves vanish. Investors are essentially betting on a binary outcome: either the company secures a major new partnership or a successful equity raise based on interim data, or it faces a severe liquidity crisis before the 2027 topline results are released.

Selected Quarter

Core Takeaway

Aligos has clinical momentum in HBV but faces a critical cash runway that may only last through 2026.

Investor Lens

The trade-off is between the high-reward potential of the B-SUPREME trial data and the immediate risk of insolvency or dilution.

Watch Next

Topline data from the Phase 2 B-SUPREME study and any new capital raise announcements.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.17Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Secured $25M upfront payment from Amoytop license agreement.

capital raise
70%
bearishMay 7

Operating losses widened to $26.9M due to increased R&D and G&A spend.

margin compression
80%
bullishMay 7

Received FDA Fast Track designation for lead HBV candidate.

regulatory action
60%
bullishMay 7

Secured $25M upfront payment from Amoytop license agreement.

capital raise
70%
bearishMay 7

Operating losses widened to $26.9M due to increased R&D and G&A spend.

margin compression
80%
bullishMay 7

Received FDA Fast Track designation for lead HBV candidate.

regulatory action
60%
bullishMay 7

Secured $25M upfront payment from Amoytop license agreement.

capital raise
70%
bearishMay 7

Operating losses widened to $26.9M due to increased R&D and G&A spend.

margin compression
80%
bullishMay 7

Received FDA Fast Track designation for lead HBV candidate.

regulatory action
60%
bullishMay 7

Secured $25M upfront payment from Amoytop license agreement.

capital raise
70%
bearishMay 7

Operating losses widened to $26.9M due to increased R&D and G&A spend.

margin compression
80%
bullishMay 7

Received FDA Fast Track designation for lead HBV candidate.

regulatory action
60%
bullishMay 7

Secured $25M upfront payment from Amoytop license agreement.

capital raise
70%
bearishMay 7

Operating losses widened to $26.9M due to increased R&D and G&A spend.

margin compression
80%
bullishMay 7

Received FDA Fast Track designation for lead HBV candidate.

regulatory action
60%
bullishMay 7

Secured $25M upfront payment from Amoytop license agreement.

capital raise
70%
bearishMay 7

Operating losses widened to $26.9M due to increased R&D and G&A spend.

margin compression
80%
bullishMay 7

Received FDA Fast Track designation for lead HBV candidate.

regulatory action
60%
bullishMay 7

Secured $25M upfront payment from Amoytop license agreement.

capital raise
70%
bearishMay 7

Operating losses widened to $26.9M due to increased R&D and G&A spend.

margin compression
80%
bullishMay 7

Received FDA Fast Track designation for lead HBV candidate.

regulatory action
60%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a stark dichotomy between clinical promise and financial instability. On the scientific front, Aligos is hitting key markers with pevifoscorvir sodium, moving into a pivotal Phase 2 study that could fundamentally re-rate the company's value. The Amoytop deal serves as a vital bridge, providing both cash and a professional endorsement of the company's capsid assembly modulator platform. However, the financial reality is a race against time. The 'going concern' warning is the dominant signal for investors, suggesting that the clinical success of the B-SUPREME trial must arrive before the cash reserves vanish. Investors are essentially betting on a binary outcome: either the company secures a major new partnership or a successful equity raise based on interim data, or it faces a severe liquidity crisis before the 2027 topline results are released.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.